At a glance
ClinicalIndex Comparison RecordN/ACompleted· 55 enrolled
Drug / intervention
RxSight RxLALdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Multi-Center Clinical Study to Evaluate Uncorrected Distance Vision and Quality of Vision After Light Treatments of an Implanted RxSight Light Adjustable Lens (RxLAL) With the Light Delivery Device (LDD) in Subjects With Preoperative Corneal Astigmatism
In Brief
A clinical study evaluating RxSight RxLAL for Cataract. Completed, enrolled 55 participants across 3 sites in 2 countries.
Detailed Summary
For patients undergoing cataract surgery, the purpose of this study is to evaluate a patient's far vision without glasses and quality of vision after implantation and UV treatment of the RxSight Light Adjustable Lens (RxLAL).Following completion of all light treatments, the patient's far vision without glasses and quality of vision will be assessed 6 months postoperatively.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
CountriesGermany, United Kingdom
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartJun 2018
First PostedDec 2018
Primary CompletionJul 2019
Study CompletionJul 2020
TodayJul 2026
First PostedDec 11, 2018
Enrollment StartJun 19, 2018
Primary CompletionJul 1, 2019
Study CompletionJul 1, 2020
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 7.6 years ago
Interventions
RxSight RxLALdevice
The patients will be assessed for 6 months